Sign In
Buy ACCD
$7.02
+0 (+0%)
At Close: Jul 07, 2025
Why Shares of Accolade Soared This Week
12:39pm, Friday, 13'th Jan 2023
Strong revenue growth and encouraging guidance pushed the stock up.
Accolade, Inc. (ACCD) Q3 2023 Earnings Call Transcript
09:58pm, Monday, 09'th Jan 2023
Accolade, Inc. (NASDAQ:ACCD ) Q3 2023 Earnings Conference Call January 9, 2023 4:30 PM ET Company Participants Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nu
Accolade (ACCD) Reports Q3 Loss, Tops Revenue Estimates
06:48pm, Monday, 09'th Jan 2023
Accolade (ACCD) delivered earnings and revenue surprises of 8.20% and 4.43%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?
Accolade to Announce Fiscal Third Quarter 2023 Financial Results
08:00am, Tuesday, 20'th Dec 2022
SEATTLE, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal third quarter 2023 financi
Accolade Inc. (ACCD) Q2 2023 Results - Earnings Call Transcript
10:39pm, Thursday, 06'th Oct 2022
Accolade Inc. (NASDAQ:ACCD ) Q2 2023 Earnings Conference Call October 6, 2022 4:30 PM ET Company Participants Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nun
Accolade (ACCD) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Thursday, 06'th Oct 2022
Accolade (ACCD) delivered earnings and revenue surprises of 7.04% and 5.68%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?
Accolade (ACCD) Expected to Beat Earnings Estimates: Should You Buy?
11:17am, Thursday, 29'th Sep 2022
Accolade (ACCD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday
08:15am, Friday, 08'th Jul 2022 Benzinga
Gainers
United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market.
Grove Collabora
This EV Maker Stock Jumps More Than 9%, Here's 46 Stocks Moving In Thursday's Mid-Day Session
04:02pm, Thursday, 07'th Jul 2022 Benzinga
Gainers
United Maritime Corporation (NASDAQ: USEA) jumped 180.4% to $8.02. The company’s stock jumped 190% on Wednesday after completing its spin-off from Seanergy Maritime Holdings Corp.
American
Accolade, Inc. (ACCD) Q1 2023 Earnings Call Transcript
07:00pm, Wednesday, 06'th Jul 2022 The Motley Fool
ACCD earnings call for the period ending March 31, 2022.
Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday
08:35am, Tuesday, 05'th Jul 2022 Benzinga
Gainers
Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64.
Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to settle at $2.85 on Friday.
Fast Radius, Inc. (NASDAQ: FSRD) jumped 41.2
Dow Surges 200 Points; Agile Therapeutics Shares Slide
06:41pm, Friday, 01'st Jul 2022 Benzinga
U.S. stocks turned higher toward the end of trading, with the Dow Jones gaining around 200 points on Friday.
The Dow traded up 0.66% to 30,977.11 while the NASDAQ rose 0.36% to 11,068.57. The S&P also
U.S. Stocks Turn Lower; Dow Tumbles Over 100 Points
04:20pm, Friday, 01'st Jul 2022 Benzinga
U.S. stocks turned lower midway through trading, with the Dow Jones dropping more than 100 points on Friday.
The Dow traded down 0.44% to 30,639.41 while the NASDAQ fell 0.59% to 10,936.46. The S&P al
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
04:06pm, Friday, 01'st Jul 2022 Benzinga
Gainers
Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday.
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 49.3% to $0.2852. Allena Pharmaceuticals
Here's Why Accolade Shares Are Trading Higher Today
12:51pm, Friday, 01'st Jul 2022
Needham analyst Ryan MacDonald reiterated a Buy rating on Accolade, Inc (NASDAQ: ACCD) with a price target of $12. Following a problematic 4QF22, he noted that Accolade bounced back nicely in
